Hugo ML Jansen’s perspective of growing his initiative through company revolution truly amazes me. Keeping the very core of your business is something most Founders forget about, and I am glad that Hugo sees that as a necessity. It is also great that he is enjoying his venture as a founder; indeed, the road to happiness is happiness itself!
Hugo ML Jansen calls himself a fallen angel on his way back home (cited from Charles Dickens). He is the CEO of Lyscaut Medical Imaging Company and a Senior consultant of nuclear medicine & molecular imaging, a clinical pharmacologist and med-tech entrepreneur.
How did you get your idea or concept for the business? What problems were you trying to solve?
Most biotech SME (drug, vaccine, probe or device) face similar challenges once they secure funding: upscaling and trialling their asset(s). These challenges rapidly cumulate with increasing asset complexity. After initial euphoria here and now, milestones and deadlines start governing day-to-day reality. Help is hard to find because of SME size and asset complexity. External expertise, tailored support and lean rapport are essential to cope.
As an expert in medical technology, what are the major issues people face when it comes to healthcare, and how has this influenced you in creating Lyscaut?
The role of medical imaging in clinical trials still is underestimated. The present trend of personalised medicine, targeted drug delivery and minimally invasive surgery all rely on molecular imaging. Molecular markers, surrogate endpoints, hybrid imaging and emerging modalities are progressively interacting with drug development.
What are the highlights of your journey as a Founder so far?
Il y a des gens qui cherchent la route du bonheur. Alors, la route c’est le bonheur. There are people looking for the road to happiness. Well then, the road is the happiness.
What risks are you currently facing and how do you deal with it?
For Lyscaut, organic growth is required in order to scale up and handle more clients. However, organic growth brings a change in both company culture and the service provided to the client. This means that company growth will affect (and change) the very core of the business model. Instead of a company evolution (process improvement & growth), we’re aiming at a company revolution (digital scalable service).
Are there any ethical concerns that your type of business must deal with? How do you overcome these ethical problems?
Health is the real wealth. There is an increasing demand for personalised healthcare in all its aspects. However, at this moment, unfortunately only for those who can afford it.
What advice would you have for anyone looking to start their own initiative?
Look in the mirror, look around you and think twice. If you really think you can do it, then do it.
Lyscaut is an independent imaging CRO (high-end expertise provider) in support of image-based clinical trials. Their unique selling point is advanced molecular imaging in the SME biotech market. Their hallmark is bringing efficiencies by building rapport.